Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 498

Results For "ABLE"

5843 News Found

Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
News | January 12, 2022

Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021

This surpasses the number of approvals supported in 2020


Amgen and Arrakis collaborate for small molecule therapeutics
Biotech | January 12, 2022

Amgen and Arrakis collaborate for small molecule therapeutics

Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen


Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
News | January 12, 2022

Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra

Ind-Ra expects revenue growth of over 12% in 2022.


Sinocompound and InCatT launch new Catalyst Screening Service
Biotech | January 12, 2022

Sinocompound and InCatT launch new Catalyst Screening Service

This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions


Covaxin booster neutralises Omicron and Delta variants: Study
News | January 12, 2022

Covaxin booster neutralises Omicron and Delta variants: Study

The study will be published on the pre-print server, medRXiv, shortly


Immune Biosolutions lead immunotherapy product neutralises Covid-19
Biotech | January 11, 2022

Immune Biosolutions lead immunotherapy product neutralises Covid-19

In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC


Pfizer and Beam enter research collaboration for In Vivo base editing programme
Biotech | January 11, 2022

Pfizer and Beam enter research collaboration for In Vivo base editing programme

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies